| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Bicycle Therapeutics Plc (BCYC) has 16 insiders with recent SEC Form 4 filings, including 10 buys and 0 sells. BCYC is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 10.02M | $40.53M | - | |
| CEO | 611.3K | $2.47M | - | |
| Dir | 196.4K | $794.5K | - | |
| Other | 159.6K | $645.4K | - | |
| COO | 136.7K | $553.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 29, 2019 | Cambridge Innovation Capital (jersey) Ltd | 10% Owner | Buy | 314,286 | $14.00 | $4,400,004.00 | +21.9% | |
| May 28, 2019 | Bingham Kate | Director | Buy | 385,715 | $14.00 | $5,400,010.00 | +25.2% | |
| May 28, 2019 | Glaxosmithkline Plc | Director, 10% Owner | Buy | 385,714 | $14.00 | $5,399,996.00 | +25.2% | |
| May 28, 2019 | Tybourne Capital Management (hk) Ltd | 10% Owner | Buy | 364,286 | $14.00 | $5,100,004.00 | +22.9% | |
| May 28, 2019 | Anstey Michael | Director | Buy | 314,286 | $14.00 | $4,400,004.00 | +21.9% | |
| May 28, 2019 | Svlsf V, LLC | 10% Owner | Buy | 385,715 | $14.00 | $5,400,010.00 | +25.2% | |
| May 28, 2019 | Harland Deborah | Director | Buy | 385,714 | $14.00 | $5,399,996.00 | +25.2% | |
| May 27, 2019 | Ng Carolyn | Director | Buy | 571,429 | $14.00 | $8,000,006.00 | New |